Castle Biosciences (NASDAQ:CSTL) Earns Outperform Rating from Analysts at Robert W. Baird

Robert W. Baird started coverage on shares of Castle Biosciences (NASDAQ:CSTL) in a report issued on Monday morning, BenzingaRatingsTable reports. The firm issued an outperform rating and a $27.00 target price on the stock.

Separately, Canaccord Genuity began coverage on shares of Castle Biosciences in a research note on Monday. They issued a buy rating and a $26.00 price target for the company. Five investment analysts have rated the stock with a buy rating, Castle Biosciences has a consensus rating of Buy and a consensus target price of $26.80.

Shares of CSTL stock opened at $19.93 on Monday. Castle Biosciences has a one year low of $17.11 and a one year high of $24.75.

In related news, Director David S. Kabakoff bought 62,500 shares of the business’s stock in a transaction dated Monday, July 29th. The stock was bought at an average price of $16.00 per share, for a total transaction of $1,000,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Mgc Venture Partners 2013 Gp, bought 312,500 shares of the business’s stock in a transaction dated Monday, July 29th. The shares were bought at an average price of $16.00 per share, with a total value of $5,000,000.00. The disclosure for this purchase can be found here.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a commercial-stage dermatological cancer, develops and commercializes diagnostic and prognostic tests for cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify stage I and II patients at high risk of metastasis based on biological information from 31 genes within their tumor tissue.

Further Reading: Outstanding Shares

Analyst Recommendations for Castle Biosciences (NASDAQ:CSTL)

Receive News & Ratings for Castle Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Castle Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.